<SEC-DOCUMENT>0001144204-18-061240.txt : 20181121
<SEC-HEADER>0001144204-18-061240.hdr.sgml : 20181121
<ACCEPTANCE-DATETIME>20181121160948
ACCESSION NUMBER:		0001144204-18-061240
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181121
FILED AS OF DATE:		20181121
DATE AS OF CHANGE:		20181121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bioblast Pharma Ltd.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		181198307

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO BLAST PHARMA LTD.
		DATE OF NAME CHANGE:	20140113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tv507746_6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 6-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of: November 2018 (Report
Number 2)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number: 001-36578</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>BIOBLAST PHARMA LTD.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name
into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>PO Box 318, Tel-Aviv, Israel 6100201</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F&nbsp;</FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Attached
hereto and incorporated by reference herein is the Registrant</FONT>&rsquo;<FONT STYLE="font-size: 10pt">s Notice of Meeting for
the Annual and Extraordinary General Meeting of Shareholders to be held on December 26, 2018, or the Meeting. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Only shareholders of record
who hold Ordinary Shares, nominal value NIS 0.05, of the Registrant at the close of trading on the Nasdaq Capital Market on November
26, 2018, will be entitled to notice of and to vote at the Meeting and any postponements or adjournments thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">The
Notice of Meeting attached to this Form 6-K of the Registrant is incorporated by reference into the registration statements on
Form S-8 (File No. 333-203114 and File No. 333-210459) of the Registrant, filed with the Securities and Exchange Commission, to
be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently
filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Exhibit No.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice
of Meeting for the Annual and Extraordinary General Meeting of Shareholders to be held on December 26, 2018.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid">Bioblast Pharma Ltd.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">(Registrant)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; width: 60%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">By:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid">/s/ Dr. Dalia Megiddo</TD></TR>
<TR STYLE="text-align: left; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Dr. Dalia Megiddo<BR> Chief Executive Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Date: November 21, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv507746_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 66pt; width: 199.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BIOBLAST PHARMA LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL
MEETING OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SHAREHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notice is hereby given that an Annual and
Extraordinary General Meeting of the Shareholders of Bioblast Pharma Ltd. (the &ldquo;<B>Company</B>&rdquo; or &ldquo;<B>Bioblast</B>&rdquo;)
will be held on December 26, 2018, at 10:00 am Israel Time, at the offices of the Company&rsquo;s Israeli counsel (Zysman, Aharoni,
Gayer &amp; Co.) at &ldquo;<FONT STYLE="background-color: white">Beit Zion,&rdquo; 41-45 Rothschild Blvd., 8<SUP>th</SUP>&nbsp;Fl.,
Tel Aviv 65784</FONT>, Israel (the &ldquo;<B>Meeting</B>&rdquo;), for the following purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">To approve certain resolutions in connection with the merger of a wholly-owned subsidiary of the Company with and into Enlivex Therapeutics Ltd. (&ldquo;<B>Enlivex</B>&rdquo;) pursuant to which Bioblast will issue a majority interest in Bioblast&rsquo;s share capital (on a post-transaction basis) to the equity-holders of Enlivex in consideration for 100% of the equity securities of Enlivex, which will become a wholly-owned subsidiary of Bioblast (the &ldquo;<B>Transaction</B>&rdquo;).&nbsp;&nbsp;In connection with the Transaction, the Company also entered into a Contingent Value Rights Agreement (&ldquo;<B>CVR Agreement</B>&rdquo;) with Enlivex and other parties that will allow the Company shareholders, as at immediately prior to closing of the Transaction, to receive proceeds from the potential sale of the Company&rsquo;s Trehalose program to a third party, if and when such sale or licensing occurs<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP></FONT>.&nbsp;&nbsp;The resolutions associated with the approval of the Transaction include the following:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="width: 91%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">To approve a reverse share split of the Company&rsquo;s ordinary shares by a ratio of up to 10:1, but not less than 4:1, to be effective at the ratio and on a date to be determined by the board of directors, and to amend the Company&rsquo;s Articles of Association accordingly.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="width: 91%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">To approve an increase of the Company&rsquo;s share capital by NIS 17,500,000, from NIS 500,000, to NIS 18,000,000, and to amend the Company&rsquo;s Articles of Association accordingly;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="width: 91%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">To approve a change of the Company&rsquo;s name to &ldquo;Enlivex Therapeutics Ltd.&rdquo; or a similar name approved by the Israeli Companies Registrar; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="width: 91%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">To approve the purchase by the Company of a &ldquo;run-off&rdquo; directors&rsquo; and officers&rsquo; liability insurance policy for a period of 3 years following the effective time of the Transaction.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt"><SUP>1</SUP> The Transaction was
announced on November 19, 2018 in a press release and a Report of Foreign Private Issuer on Form 6-K that was furnished to the
U.S. Securities and Exchange Commission on November 19, 2018 (the &ldquo;<B>6-K Report</B>&rdquo;). A copy of the Merger Agreement
relating to the Transaction was attached as Exhibit 99.1 to the 6-K Report. A copy of the CVR Agreement is attached as Exhibit
99.2 to the 6-K Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Transaction will not be completed
if Item No. 1 is not approved.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">To re-appoint Kost, Forer, Gabbay &amp; Kasierer (a member of Ernst &amp; Young Global) as the Company&rsquo;s independent registered public accounting firm until the next Annual Meeting and to authorize the Company&rsquo;s Board of Directors to determine such accounting firm&rsquo;s compensation for the fiscal year ending December 31, 2018.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">To re-elect Dr. Dalia Megiddo as a Director of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">To elect Mr. Gili Cohen, Mr. Eyal Gibor, Mr. Tomer Yossef and Mr. Ran Weinstock as Directors of the Company and determine such persons&rsquo; compensation terms.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">To approve the engagement terms of Dr. Dalia Megiddo in her position as the Company&rsquo;s interim Chief Executive Officer and in connection with intellectual property services she provided to the Company.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">6.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">To approve the terms of engagement of the Company with Mr. Oren Elmaliah, the Company&rsquo;s principal financial officer.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">7.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">To approve the Company&rsquo;s purchase of Directors and Officers insurance policies.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">8.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">To present the financial statements of the Company for the fiscal year ended December 31, 2017.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS
THAT YOU VOTE &ldquo;FOR&rdquo; ALL OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE PROPOSALS ON THE AGENDA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Record Date and Right to Vote</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the provisions of Israeli law
and the Articles, only shareholders of record as of the close of trading on the Nasdaq Capital Market on November 26, 2018 (&ldquo;<B>Record
Date</B>&rdquo;) are entitled to attend and vote at the Meeting and any adjournments or postponements thereof. They are also entitled
to receive notice of the Meeting and to vote at the Meeting if they held ordinary shares of the Company par value NIS 0.05 per
share (&ldquo;<B>Ordinary Shares</B>&rdquo;) through a bank, broker or other nominee which was one of the Company&rsquo;s shareholders
of record at the close of business on the Record Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">A
shareholder whose Ordinary Shares are registered in his, her, or its benefit with a member of a stock exchange and are included
in the Ordinary Shares which are registered in the register of shareholders of the Company under the name of such member of a stock
exchange, shall be required to prove ownership of such Ordinary Shares as of the Record Date by providing the Company, before the
time appointed for holding the Meeting, with proof of ownership, issued by a member of a stock exchange, or a copy of the shareholder&rsquo;s
Identification Card, passport, or Incorporation Certificate, if such shareholder is registered in the register of shareholders
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Legal Quorum</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Articles, no business may be
transacted at any shareholders meeting unless a quorum is present when the meeting begins.&nbsp;The quorum required for a meeting
is the presence, in person or by proxy or by a voting deed, of at least two shareholders, holding in the aggregate at least one
third of the issued and outstanding Ordinary Shares as of the Record Date (&ldquo;<B>Quorum</B>&rdquo;).&nbsp;If within an hour
from the time appointed for holding a meeting a Quorum is not present, the meeting shall be dissolved and it shall stand adjourned
to the same day in the next week (or the business day following such day, if such day is not a business day) at the same time and
place and two shareholders then present at such adjourned meeting, in person or by proxy or by a voting deed, shall constitute
a Quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Abstentions are counted in determining
if a Quorum is present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Proxy</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the Record Date, the full text
of the proposed resolutions for the Meeting, together with the proxy statement providing an overview of the Transaction and other
matters relating thereto, and the form of proxy card for the Meeting, will be furnished to the SEC and then mailed to shareholders
of record as of the Record Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You can vote your shares by attending the
Meeting or by completing and signing a proxy card. If you are voting by proxy (in the case of a record shareholder) or instructing
your bank, broker or other nominee how to vote via the proxy card (for a shareholder holding in street name), please follow the
instructions on the proxy card. We encourage all shareholders to vote or instruct their bank, broker or other nominee how to vote
via proxy, even if attending the Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will mail copies of this invitation
with the proxy, after it is furnished to the SEC and the proxy card to our shareholders of record as of the Record Date, and we
will solicit proxies primarily by mail and e-mail. The original solicitation of proxies by mail and e-mail may be further supplemented
by solicitation by telephone, mail, e-mail and other means by certain of our officers, directors and employees (who will not receive
additional compensation for these services). We will bear the cost of external solicitors and of the solicitation of the proxy
cards, including postage, printing and handling, and will reimburse the reasonable expenses of brokerage firms and others for forwarding
material to beneficial owners of our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Proxy cards should be completed, signed
and returned in the envelope to be enclosed. If you instead send your proxy card directly to the Company&rsquo;s legal counsel
offices as permitted below, we will not be able to count it unless we receive it, accompanied by (a) a copy of the shareholder&rsquo;s
Identification Card, passport, or Incorporation Certificate (if applicable), with respect to a shareholder who is registered in
the register of shareholders of the Company, or (b) proof of ownership, as specified above, with respect to a shareholder whose
shares are registered under the name of a bank, broker or other nominee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will not be able to count a proxy card
unless we receive it at the offices of our Israeli legal counsel, Zysman, Aharoni, Gayer &amp; Co. at &ldquo;<FONT STYLE="background-color: white">Beit
Zion,&rdquo; 41-45 Rothschild Blvd., 8<SUP>th</SUP>&nbsp;Fl., Tel Aviv 65784</FONT>, Israel, by December 26, 2018 at 6:00 am Israel
time, (together with the foregoing proof of ownership). If mailing your proxy card in the enclosed envelope, it must be actually
received by our transfer agent, Vstock Transfer, LLC, at 18 Lafayette Place, Woodmere, NY 11598 in the enclosed envelope, by 3:00
pm Eastern time on December 25, 2018 (an earlier deadline may apply for shares held in street name, as may be indicated in the
instructions provided to you with your proxy card).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you sign and return the enclosed proxy
card, your shares will be voted as abstained with respect to all of the proposed resolutions, whether or not you specifically indicate
a &ldquo;ABSTAIN&rdquo; vote, unless you specifically vote in favor or vote against a specific resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The vote with respect to Items No. 1, 4,
5, 6 and 7 of the Meeting&rsquo;s agenda will not be counted without indication of non-existence of personal interest and that
you are not a controlling shareholder, as such term is defined under the Companies Law. The proxy card to be mailed will include
instructions on how to make this indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On all matters considered at the Meeting,
abstentions will be treated as neither a vote &ldquo;FOR&rdquo; nor &ldquo;AGAINST&rdquo; the matter, although they will be counted
in determining if a Quorum is present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>YOUR VOTE IS IMPORTANT REGARDLESS OF
THE NUMBER OF ORDINARY SHARES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>YOU OWN. ACCORDINGLY, YOU ARE REQUESTED TO PROMPTLY COMPLETE, SIGN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AND DATE THE ENCLOSED PROXY CARD
AND RETURN IT IN THE ENVELOPE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROVIDED, WHETHER OR NOT YOU PLAN TO ATTEND THE MEETING.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Disclosure Regarding Compensation</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New regulations under the Israeli Companies
Law require that the Company provides its shareholders with certain information about the compensation granted to the Company&rsquo;s
five most highly compensated officers during or with respect to the year ended December 31, 2017. Such information can be found
under Item 6.B. of the Company&rsquo;s Annual Report on Form 20-F for the year ended December 31, 2017 filed with the Securities
and Exchange Commission on April 23, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.35pt 0pt 146.35pt; text-align: justify; text-indent: 33.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 35%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">By order of the Board of Directors,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>/s/ Dr. Dalia Megiddo</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>Dr. Dalia Megiddo</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Chief Executive Officer </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">November 21, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !8 0H# 2(  A$! Q$!_\0
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M=<$\$GJ!_AV4Z?M,-RQ:OS;72Z'/*7+6NUI;]3UJO-?C=M_X0FUW=?MZ;?\
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I"!@$<T44O:2O<.16L:-C;M:6<<#RF5U'+E0,G.>E6***EN[N6E;0_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
